While the latter category shows a variable outcome with patients with aggressive histologies and/or advanced stage suffering of adverse outcome, prognosis of systemic T-cell NHL is generally poor with conventional treatment, with the notable exception of low-risk, ALK positive, anaplastic large cell lymphoma (ALCL) patients [8, 9]. The gene discussed is ALK; the disease is T-cell non-Hodgkin lymphoma.